Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population

AIDS

Volumn 14, Issue 4, 2000, Pages 357-366

  Bangsberg, David R ^a,b   Hecht, Frederick M ^b   Charlebois, Edwin D ^a   Zolopa, Andrew R ^c   Holodniy, Mark ^c,d   Sheiner, Lewis ^b   Bamberger, Joshua D ^e   Chesney, Margaret A ^b   Moss, Andrew ^b  

^a Epidemiol and Prev I (EPI) C   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

Access to therapy; Adherence; Highly active antiretroviral therapy; HIV; Homeless; Injection drug use; Protease inhibitor; Resistance; Viral load

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; REGRESSION ANALYSIS; SELF REPORT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV PROTEASE INHIBITORS; HIV-1; HOMELESS PERSONS; HUMANS; MALE; MEDICAL INDIGENCY; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 0034027217     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200003100-00008     Document Type: Article

References (32)

1. 1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. 2. Ventura SJ, Anderson RN, Martin JA, Smith BL. Births and deaths: preliminary data for 1997. Natl Vital Stat Rep 1998, 47:1-41.
3. 3. Centers for Disease Control and Prevention. Update: trends in AIDS incidence - United States, 1996. MMWR 1997, 46: 861-867.
4. 4. Hecht FM, Colfax G, Swanson M, Chesney MA. Adherence and effectiveness of protease inhibitors in clinical practice. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, 1998, [abstract 151].
5. 5. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996, 276:1955-1956.
6. 6. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998, 279:930-937.
7. 7. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998, 279:1977-1983.
8. 8. Altice FL, Friedland GH. The era of adherence to HIV therapy [Editorial]. Ann Intern Med 1998, 129:503-505.
9. 9. Cohen OJ, Fauci AS. Transmission of multidrug-resistant human immunodeficiency virus - the wake-up call [Editorial; Comment]. N Engl J Med 1998, 339:341-343.
10. 10. Mayers DL. Drug-resistant HIV-1: the virus strikes back [Editorial; Comment]. JAMA 1998, 279:2000-2002.
11. 11. Paes AH, Bakker A, Soe-Agnie CJ. Measurement of patient compliance. Pharm World Sci 1998, 20:73-77.
12. 12. Straka RJ, Fish JT, Benson SR, Suh JT. Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy 1997, 17:126-132.
13. 13. Hales G, Mitchel J, Smith DE, Kippex S. Validity of patient questioning versus pill count as an assessment of compliance. 12th World AIDS Conference, Geneva, 1998, [abstract, 32373].
14. 14. Melbournem K, Geketko S, Brown S, Wiley C, Chase S, Fisher A. Electronic adherence assessment versus self-report in HIV-infected individuals. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 1998, [abstract 175].
15. 15. Matsuyama JR, Mason BJ, Jue SG. Pharmacists, interventions using an electronic medication-event monitoring device's adherence data versus pill counts. Ann Pharmacother 1993, 27: 851-855.
16. 16. Olivieri NF, Matsui D, Hermann C, Koren G. Compliance assessed by the Medication Event Monitoring System. Arch Dis Child 1991, 66:1399-1402.
17. 17. Zolopa AR, Hahn JA, Gorter R, et al. HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample. JAMA 1994, 272:455-461.
18. 18. Gilbert JR, Evans CE, Haynes RB, Tugwell P. Predicting compliance with a regimen of digoxin therapy in family practice. Can Med Assoc J 1980, 123:119-122.
19. 19. Paterson D, Swindells S, Mohr J, et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
20. 20. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999, 353:863-868.
21. 21. Zolopa AR, Warford A, Montoya J, Hsu P, Katzenstein D, Merigan T, Efron B. HIV-1 genotypic resistance patterns predict response to saquinavir/ritonavir in patients who have failed prior protease inhibitors. Ann Intern Med 1999, 131: 813-821.
22. 22. Cunningham P, Kaufman GR, Sayer D, Smith D, French M, Cooper D. A. Pre-existent mutations of the HIV protease gene were associated with therapeutic failures in patients on saquinavire/ritonavir therapy. 12th World AIDS Conference, Geneva, 1998, [abstract 32294].
23. 23. Craig C, Race E, Sheldon J, et al. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS 1998, 12:1611-1618.
24. 24. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999, 13:1099-1107.
25. 25. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologie failure and adverse drug reactions. Ann Intern Med 1999, 131:81-87.
26. 26. Gallant J, Block D. Adherence to antiretroviral regimens in HIV-infected patients: results of a survey among patients and physicians. J Int Assoc Physicians AIDS Care 1998, 4:32-35.
27. 27. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998, 280:544-546.
28. 28. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998, 280:547-549.
29. 29. Bangsberg D, Moss A. When should we delay highly active antiretroviral therapy? J Gen Intern Med 1999, 14:446-448.
30. 30. Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA 1997, 278:63-65.
31. 31. Lerner BH, Gulick RM, Dubler NN. Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease. Ann Intern Med 1998, 129:573-578.
32. 32. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team [see Comments]. N Engl J Med 1998, 339:1261-1268.